Changeflow GovPing Healthcare & Life Sciences TS-172 Hyperphosphatemia Hemodialysis Phase 3 S...
Routine Notice Added Final

TS-172 Hyperphosphatemia Hemodialysis Phase 3 Study

Email

Summary

A Phase 3 clinical trial (NCT07548840) is registered on ClinicalTrials.gov evaluating TS-172 for treatment of hyperphosphatemia in patients undergoing hemodialysis. The study is categorized under Phase 3 interventional trials sorted by start date.

Published by NIH on clinicaltrials.gov . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors ClinicalTrials.gov - Phase 3 Trials by Start Date for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 3 changes logged to date.

What changed

A new Phase 3 clinical trial has been registered with ClinicalTrials.gov under identifier NCT07548840. The study will evaluate TS-172 as a treatment for hyperphosphatemia in patients receiving hemodialysis. This registry entry provides publicly accessible information about the trial's scope and classification.

Pharmaceutical companies sponsoring or conducting late-stage renal or metabolic drug trials should monitor ClinicalTrials.gov for competitive landscape awareness regarding hyperphosphatemia treatments in the hemodialysis population.

Archived snapshot

Apr 23, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

Show glossary

Get daily alerts for ClinicalTrials.gov - Phase 3 Trials by Start Date

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from NIH.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
NIH
Instrument
Notice
Branch
Executive
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
NCT07548840

Who this affects

Applies to
Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Clinical trial conduct Drug development
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Clinical Operations
Topics
Healthcare Clinical Operations

Get alerts for this source

We'll email you when ClinicalTrials.gov - Phase 3 Trials by Start Date publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!